The Latest Breaking News from Pfizer

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday.

Previously, fall is when Americans would typically receive their vaccines

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

The video was produced by RT and provides a disclaimer about its true nature towards the end.

Lobbying firms with ties to Donald Trump's MAGA movement are reaping record profits as corporations race to secure influence in Washington, signalling a lucrative new era for political lobbying under Trump 2.0.